Published in J Antimicrob Chemother on August 21, 2007
HIV Medication Adherence in Underserved Populations | NCT02392884
Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One (2011) 2.84
Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol (2013) 2.64
The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health (2009) 2.48
Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med (2010) 1.71
Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther (2010) 1.63
Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr (2011) 1.55
Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke (2010) 1.44
Gender-related mortality for HIV-infected patients on highly active antiretroviral therapy (HAART) in rural Uganda. Int J Womens Health (2010) 1.37
How long is the window of opportunity between adherence failure and virologic failure on efavirenz-based HAART? HIV Clin Trials (2008) 1.25
Adherence to antiretroviral therapy and clinical outcomes among young adults reporting high-risk sexual behavior, including men who have sex with men, in coastal Kenya. AIDS Behav (2013) 1.22
Women-specific HIV/AIDS services: identifying and defining the components of holistic service delivery for women living with HIV/AIDS. J Int AIDS Soc (2013) 1.21
Long-Term Outcome of an HIV-Treatment Programme in Rural Africa: Viral Suppression despite Early Mortality. AIDS Res Treat (2010) 1.16
The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review. J Behav Med (2009) 1.14
Gender differences in immune reconstitution: a multicentric cohort analysis in sub-Saharan Africa. PLoS One (2012) 1.10
Caring for women living with HIV: gaps in the evidence. J Int AIDS Soc (2013) 1.07
The influence of different types of alcoholic beverages on disrupting highly active antiretroviral treatment (HAART) outcome. Alcohol Alcohol (2009) 0.98
Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study. AIDS Res Hum Retroviruses (2013) 0.97
Gender inequities in quality of care among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000-2010). PLoS One (2014) 0.93
X chromosomal variation is associated with slow progression to AIDS in HIV-1-infected women. Am J Hum Genet (2009) 0.92
Temporal trends in the discontinuation of first-line antiretroviral therapy. J Antimicrob Chemother (2014) 0.91
Alcohol consumption and CD4 T-cell count response among persons initiating antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 0.89
Sex differences in HIV outcomes in the highly active antiretroviral therapy era: a systematic review. AIDS Res Hum Retroviruses (2014) 0.88
Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review. AIDS Res Hum Retroviruses (2015) 0.86
Individual and contextual factors of influence on adherence to antiretrovirals among people attending public clinics in Rio de Janeiro, Brazil. BMC Public Health (2013) 0.86
Gender differences in clinical outcomes among HIV-positive individuals on antiretroviral therapy in Canada: a multisite cohort study. PLoS One (2013) 0.86
Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women. Antimicrob Agents Chemother (2014) 0.85
Gender differences in clinical, immunological, and virological outcomes in highly active antiretroviral-treated HIV-HCV coinfected patients. Patient Prefer Adherence (2010) 0.85
Sex and Racial/Ethnic Differences in Premature Mortality Due to HIV: Florida, 2000-2009. Public Health Rep (2015) 0.82
Adult HIV care resources, management practices and patient characteristics in the Phase 1 IeDEA Central Africa cohort. J Int AIDS Soc (2012) 0.82
Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care. J Int AIDS Soc (2015) 0.79
Pregnant women with HIV in rural Nigeria have higher rates of antiretroviral treatment initiation, but similar loss to follow-up as non-pregnant women and men. Int Health (2015) 0.79
Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study. BMC Infect Dis (2013) 0.79
Asking the right questions: developing evidence-based strategies for treating HIV in women and children. BMC Public Health (2011) 0.78
Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV. Curr HIV Res (2013) 0.78
Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials (2015) 0.77
CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy. AIDS Res Treat (2011) 0.77
Immigrant women living with HIV in Spain: a qualitative approach to encourage medical follow-up. BMC Public Health (2014) 0.76
Epidemiological surveillance of the HIV/AIDS complex through the analysis of trends in the incidence of Kaposi's sarcoma in Cali, Colombia. Colomb Med (Cali) (2012) 0.75
Beyond the Brain: The Role of Brain-Derived Neurotrophic Factor in Viroimmune Responses to Antiretroviral Therapy among People Living with HIV with and without Alcohol Use. J Int Assoc Provid AIDS Care (2014) 0.75
Barriers to a cure for HIV in women. J Int AIDS Soc (2016) 0.75
How are women living with HIV in France coping with their perceived side effects of antiretroviral therapy? Results from the EVE study. PLoS One (2017) 0.75
Predictors of HIV virological failure and drug resistance in Chinese patients after 48 months of antiretroviral treatment, 2008-2012: a prospective cohort study. BMJ Open (2017) 0.75
The association between HIV (treatment), pregnancy serum lipid concentrations and pregnancy outcomes: a systematic review. BMC Infect Dis (2017) 0.75
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 4.57
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS (2005) 4.40
Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr (2007) 4.30
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr (2002) 3.55
Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol (2004) 3.06
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 2.81
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr (2010) 2.59
Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav (2004) 2.53
Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood (2012) 2.51
Mode of infant feeding and HIV infection in children in a program for prevention of mother-to-child transmission in Uganda. AIDS (2005) 2.48
Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet (2002) 2.44
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. J Infect Dis (2004) 2.21
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11
The extraordinary ligand binding properties of human serum albumin. IUBMB Life (2005) 2.00
Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology (2009) 1.99
Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol (2005) 1.87
Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr (2009) 1.81
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med (2006) 1.65
A relapsing inflammatory syndrome and active human herpesvirus 8 infection. N Engl J Med (2005) 1.63
Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther (2012) 1.57
Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. PLoS One (2008) 1.56
Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS (2005) 1.55
Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses (2005) 1.52
Kaposi's sarcoma in transplant and HIV-infected patients: an epidemiologic study in Italy and France. Transplantation (2005) 1.52
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS (2006) 1.52
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis (2003) 1.51
Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications. Int J Mol Sci (2013) 1.50
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis (2014) 1.47
Late presenters in an HIV surveillance system in Italy during the period 1992-2006. J Acquir Immune Defic Syndr (2008) 1.47
Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis (2003) 1.47
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses (2002) 1.45
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. New Microbiol (2015) 1.45
Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr (2003) 1.44
Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation. Retrovirology (2015) 1.43
Decline in esophageal candidiasis and use of antimycotics in European patients with HIV. Am J Gastroenterol (2005) 1.42
Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2006) 1.41
The effect of sex/gender on cardiovascular pharmacology. Curr Pharm Des (2011) 1.41
Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer (2007) 1.40
Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda. J Med Virol (2007) 1.39
Gender differences in the treatment of HIV infection. Pharmacol Res (2008) 1.39
European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev (2011) 1.38
Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program. J Acquir Immune Defic Syndr (2007) 1.38
Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS (2005) 1.37
Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS (2003) 1.37
Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol (2003) 1.36
Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. J Med Virol (2005) 1.32
Calibrated real-time PCR assay for quantitation of human herpesvirus 8 DNA in biological fluids. J Clin Microbiol (2002) 1.32
Prosthetic joint infections: microbiology, diagnosis, management and prevention. Int J Antimicrob Agents (2008) 1.30
Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retroviruses (2003) 1.29
Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with <50copies/ml HIV-1 RNA. J Clin Virol (2009) 1.28
HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS. Curr HIV Res (2011) 1.28
Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? AIDS (2008) 1.25
Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr (2012) 1.25
Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges. Curr Opin HIV AIDS (2013) 1.23
Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.21
Methicillin-resistant Staphylococcus aureus: the superbug. Int J Infect Dis (2010) 1.20
The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol (2007) 1.20
Leishmania infantum leishmaniasis in corticosteroid--treated patients. BMC Infect Dis (2006) 1.19
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One (2012) 1.17
CD4+ T lymphocyte recovery in individuals with type 1 human immunodeficiency virus infection. Clin Infect Dis (2010) 1.15
Proton dynamics in cancer. J Transl Med (2010) 1.14
Primary human herpesvirus 8 infection in immunocompetent children. JAMA (2002) 1.13
Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay. J Clin Virol (2009) 1.13
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Curr HIV Res (2009) 1.12
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother (2006) 1.11
Single-nucleotide polymorphisms in human beta-defensin-1 gene in Mozambican HIV-1-infected women and correlation with virologic parameters. AIDS (2008) 1.10
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infect Dis (2012) 1.10
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol (2012) 1.10
Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J Infect Dis (2004) 1.09
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis (2012) 1.09
Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther (2004) 1.07
Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. FASEB J (2013) 1.06